41 results about "Tumour site" patented technology

The invention relates to a cell membrane bionic drug-loaded carbon dot nano-material as well as a preparation method and application thereof. The nano-composite is prepared by the following steps: preparing carbon dots, cross-linking to form a reduction responsive carbon dot nano-cluster, sequentially loading chemotherapeutic drugs and coating a cancer cell membrane to form a nano-vaccine. After the nano vaccine is injected into the body of a mouse through caudal vein, the enrichment of the nano vaccine in a tumor part can be enhanced by utilizing the active tumor targeting characteristic of a cancer cell membrane, and tumor cells can be induced to generate immunogenic death through carried chemotherapy drugs and photothermal therapy, so that chemotherapy / photothermal / immune combined therapy on tumors is realized; the obvious anti-tumor effect is realized. In addition, as a nano vaccine, after subcutaneous injection, the nano vaccine can also utilize the tumor antigen carried by a cancer cell membrane and the adjuvant characteristics of the carbon dots to activate the anti-tumor immunity of an organism so as to prevent tumors, and has potential clinical application value.

This invention is related to the fields of medical biotechnology, nanobiotechnology, and nanomedicine. It involves a nanomedicine product that can release HOC1 (hypochlorous acid) at the tumor site in a controlled manner to treat lung cancer. HOC1 is a potent antimicrobial and antitumor agent that can target tumor tissues while minimizing damage to healthy tissues. The produced nanoparticles have a two-layer structure: the inner layer contains alginate, PFP (perfluoropentane), and Ca(OCl)2 to release HOC1, and the outer layer has a chitosan coating with folate and salicylic acid for targeting and proton release. The production process involves nanoemulsion and coating with the ionic gelation technique. When the nanoparticles are delivered to the lungs and targeted to cancer cells with folate, ultrasound radiation triggers the release of HOC1 to induce apoptosis and destroy cancer cells effectively, reducing side effects and improving treatment outcomes for lung cancer patients.

The application relates to the field of nanobiomedicine, and particularly relates to an engineered vesicle and a preparation method and application thereof. The engineered vesicle comprises a nano-vesicle and a calcium phosphate mineralized film coated on the surface of the nano-vesicle, and the nano-vesicle contains p53 protein. The p53 protein contained in the engineered vesicle promotes tumor aging to inhibit proliferation and metastasis, and the aged tumor cells can enhance the immune response against tumors at the tumor site, and the outer calcium phosphate mineralized film coating enables the nano-vesicle particles to effectively reduce the risk of severe inflammation in the body, to be gathered at the tumor site by the EPR effect, and under the acidic tumor microenvironment, the pH-sensitive calcium phosphate mineralized film is broken to expose the vesicle with certain immune stimulating capacity, which synergistically activates the immune response against tumors. The engineered vesicle has wide application prospects, and also lays a foundation for the design and development of a corresponding drug delivery system.

The invention discloses a compound targeting AT1R, which is composed of a target head molecule targeting AT1R, a PEG linker, an aspartic acid linker and a chelating agent, and can be used as a component of a PET tracer agent targeting AT1R. A target head molecule can be embedded into a hydrophobic'pocket 'of AT1R protein, so that high-affinity and high-selectivity targeted binding is realized; the PEG connexon can prolong the residence time of the PET tracer agent targeting the AT1R at the tumor part; different numbers of aspartic acids can regulate and control the pharmacokinetic properties of the PET tracer agent targeting the AT1R, reduce the liver and gall and intestinal signal backgrounds of the PET tracer agent targeting the AT1R, and improve the target-to-cost ratio. Therefore, accurate diagnosis and treatment of digestive system diseases such as digestive tract tumor and liver cancer can be realized. The invention further discloses a PET tracer agent targeting AT1R as well as a preparation method and application of the PET tracer agent.

The invention relates to an ultrasonic response type copper molybdate nano material as well as a preparation method and application thereof. The chemical formula of the nano material is HCu1. 5MoO5. The preparation method comprises the following steps: mixing a molybdenum source, urea and a copper source in water, cooling, crystallizing, and carrying out ultrasonic treatment. Compared with the prior art, the nano material can synchronously generate active oxygen and controllably release copper ions at a tumor site under the accurate control of exogenous ultrasound, and efficiently subvert the copper steady state in tumor cells through the biaxial synergistic effect of'efflux inhibition 'and'internal supply enhancement', so that copper death is specifically induced, and the tumor cell apoptosis is inhibited. And anti-tumor immune response is synergistically activated, so that effective application in treatment of bladder cancer by inducing copper death, especially in treatment of malignant solid tumors such as bladder cancer and pancreatic cancer, is realized.

The application discloses a sequential anti-tumor strategy based on improvement of tumor microenvironment (TME) combined with CAR T and application thereof, and belongs to the technical field of biological medicine, which simultaneously improves tumor fibrosis and acid microenvironment by applying tumor-related fibroblast (CAF) targeting drugs and proton pump inhibitors, and sequentially injects CAR T combined therapy for solid tumors, wherein the CAF targeting drugs are selected from tretinoin, calcipotriol, losartan and minnelide, the proton pump inhibitors are selected from lansoprazole, omeprazole, pantoprazole, rabeprazole and esomeprazole, and the CAR T receptor or ligand is selected from mesothelin, protein tyrosine kinase 7, NKG2D, CD47, B7-H3, MUC1 and HER2; the sequential administration strategy first destroys the dense physical barrier of the tumor microenvironment, improves the acidity of the tumor site, ensures the infiltration, survival and proliferation of CAR T at the tumor site, and then targets and inhibits the growth of solid tumors, especially high-malignancy triple-negative breast cancer, by using the specificity of CAR T.

The invention relates to the technical field of biological medicine, in particular to a cyclic peptide conjugate and application thereof. The invention provides a cyclic peptide conjugate targeting fibroblast activating protein and application of the cyclic peptide conjugate. The cyclopeptide conjugate not only improves the uptake value of the fibroblast activated protein targeting compound at the tumor site, but also reduces the uptake value at the kidney site.

The present disclosure provides a nanocomposite and a preparation method and use thereof. In the present disclosure, the nanocomposite is wrapped with Prussian blue nanoparticles (PB) using a platelet membrane (PM) as a shell; and a surface of the PM is modified with an aptamer of cancer cells and horseradish peroxidase (HRP). An ability of platelets (PLTs) to specifically target cancer cells and inflammatory sites can effectively enhance the accumulation of nanoparticles at tumor sites, and help PB better achieve a desirable photothermal therapy (PTT) under near-infrared light irradiation. In addition, hydrogen peroxide is highly expressed in the tumor microenvironment; the HRP modified on a surface of the nanocomposite can decompose the hydrogen peroxide to generate oxygen bubbles, which drive active transport of the nanocomposite, thereby enhancing the accumulation in cancer cells. Modification with the aptamer of cancer cells on a platelet membrane surface enhances cancer cell targeting.

A method for treating a tumor excise site defined by a center and edges is described. The method includes simultaneously exposing the tumor site to radiation containing fluid and pulsating thermally treated fluid, wherein the fluids are separate from each other and confined to a balloon. Also disclosed is a device for treating a tumor excise site defined by a center and edges. The device includes a reversibly deformable container positioned at the center, the container encapsulating thermally treated fluid; a first drainage conduit; and a second radio-isotope containing conduit contacting a second longitudinally extending surface of the first drainage conduit so as to be positioned between the first drainage conduit and the center.

The invention discloses a polypeptide ligand targeting fibroblast activating protein and application of the polypeptide ligand. Part of the structure in the cyclopeptide skeleton of the ligand is a peptide mimetic skeleton structure aiming at an FAP target, the specific binding force with the FAP is stronger, the ligand has stronger FAP targeting, higher tumor specificity and faster kidney clearance rate, and the retention time at a tumor part is longer, so that the ligand has an obvious inhibiting effect on the FAP and can be used as or used for preparing an FAP inhibitor; the compound can be connected with one of a fluorophore, a radionuclide for diagnosis, a chelating group containing the radionuclide for diagnosis and the like to serve as or be used for preparing a developing agent for developing tumors, inflammatory sites, infected sites and the like. The polypeptide can be connected with one of therapeutic radionuclide, a chelating group containing the therapeutic radionuclide, a cytotoxin group, other functional groups and the like to serve as or be used for preparing targeted polypeptide coupling drugs for treating diseases such as tumors, inflammations, infection and the like; the effect is good, the safety is high and the application is wide.

A nanobowl-supported drug-loaded liposome, a preparation method therefor, and an application thereof. The preparation method for the nanobowl-supported drug-loaded liposome comprises: incubating and ultrasonically treating a nanobowl and a liposome and then successfully encapsulating a drug by utilizing an ammonium sulfate active drug loading method to obtain the nanobowl-supported drug-loaded liposome. The nanobowl-supported drug-loaded liposome can resist the influence of plasma proteins and blood flow shearing forces on drug leakage, enhance the delivery of the drug at a tumor site, improve carrier stability, and improve an anti-tumor curative effect.

The invention provides a polypeptide as well as a conjugate and application thereof. Wherein the polypeptide has an amino acid sequence as shown in SEQ ID NO: 1, and the amino acid represented by X at the 14th site and / or the 39th site has the following characteristics: the amino acid can be coupled with a modifier, and can be uncoupled with the modifier in a tumor microenvironment to release the polypeptide; wherein the binding capacity of the polypeptide which is not coupled with the modifier and the CD122 is marked as the first binding capacity, the binding capacity of the polypeptide which is coupled with the modifier and the CD122 is marked as the second binding capacity, the ratio of the first binding capacity to the second binding capacity is marked as n, and n is larger than or equal to 5. Under the action of a tumor specific enzyme, the polypeptide is prevented from activating NK cells and CD8 + T cells in peripheral circulation due to shielding of the modifier, and under the action of the tumor specific enzyme, the polypeptide is uncoupled from the conjugate and recovers activation of an IL2-R beta gamma receptor, so that a specific killing effect is achieved at a tumor part.

The present application belongs to the technical field of nanometer material preparation, and relates to a kind of nanometer medicine, including medicine carrier and active ingredient, medicine carrier adopts amphiphilic polymer, and active ingredient includes photosensitizer Ce6 and analgesic drug LC. The preparation method of the nanometer medicine is also disclosed, comprising the following steps: weighing Ce6, analgesic drug LC and amphiphilic polymer, dissolving in solvent to obtain a mixed solution; the mixed solution is stirred uniformly, and dialyzed in ultrapure water; the solution obtained by dialysis is constant volume, and filtered to obtain nanometer medicine. The nanometer medicine particle size morphology is regular, the particle size is uniform, has good stability within 7 days, can have good enrichment effect at tumor site, and has good photodynamic therapy effect. Lidocaine and photosensitizer reach the lesion site at the same time through intravenous injection, not only reduce the operation steps, but also target the lesion site, reduce the anxiety of patients because they feel that anesthesia will affect intelligence.

The application discloses a kind of cannabidiol heat-sensitive nano hydrogel preparation and its injection and its preparation method, the injection includes cannabidiol 5-15mg / mL, Poly (I:C) 0.5-1.5mg / mL and Pluronic F127 concentration is 20-30wt%.The injection can slow-release cannabidiol and Poly (I:C) and prolong its residence time at tumor site, reduce dosing frequency, effectively and continuously synergistic inhibition tumor, reduce side effects.

A suspension comprising radioactive microspheres. The radioactive microsphere comprises a resin microsphere and a radionuclide loaded on the resin microsphere, wherein the average particle size of the radioactive microsphere is 25 μm to 40 μm. By means of controlling the proportion of non-spherical microspheres in the radioactive microspheres to be within 5%, the distribution density of the microspheres at a tumor part is increased, the effect of killing tumors is improved, and the treatment safety is improved.

The application provides a nano regulator and a preparation method and application thereof. Specifically, water regulation drugs and chemotherapy drugs are co-delivered through metal organic framework nanoparticles or metal polyphenol nanoparticles, the tumor-targeted enrichment and microenvironment-responsive release characteristics of the nano regulator are utilized to release the chemotherapy drugs at the tumor site after cryoablation. The nano regulator can be used for cryoablation sensitization and chemotherapy synergistic treatment, thereby effectively improving the tumor inhibition effect.

The present invention belongs to the field of medicine and relates to use of an iron-loaded carbon nanoparticle suspension injection for combined administration. The iron-loaded carbon nanoparticle suspension injection is administered in combination with an anticancer drug to inhibit tumor growth. In the combined administration, the anticancer drug is administered orally or intravenously, and the iron-loaded carbon nanoparticle suspension injection is administered via intratumoral injection. After the iron-loaded carbon nanoparticle suspension injection is injected into a tumor, it is found that the anticancer drug administered orally or intravenously is enriched in the tumor, thereby increasing the concentration of the anticancer drug in the tumor, enabling the anticancer drug to more accurately act on the tumor site, and reducing the dose of the anticancer drug and its toxic side effects on normal cells and tissues. The combined administration of the iron-loaded carbon nanoparticle suspension injection and the anticancer drug has a synergistic effect.

The application provides an embolism microsphere for regulating a tumor microenvironment and a preparation method and application thereof. The prepared embolism microsphere for regulating the tumor microenvironment is used for arterial tumor embolism, can embolize tumor blood vessels, block nutrition supply at a tumor site, and slowly and continuously release hydroxide in situ, neutralize lactic acid in the tumor microenvironment, regulate the weakly acidic tumor microenvironment, and improve the effect of chemotherapy, radiotherapy and immunotherapy.

The invention relates to the technical field of biological materials, in particular to a combretastatin targeted lipid drug delivery system and a preparation method thereof. According to the method, AS1411 and ApoE peptides are adopted to carry out joint modification on CA4 / HM-Fe lipidosome. Fe < 3 + > is introduced on the basis of the sound-sensitive agent HMME, so that the sound-sensitive agent HMME and the sound-sensitive agent HMME are self-assembled to form an HM-Fe complex, CA4 and free HMME are entrapped in a hydrophobic region, and HM-Fe is entrapped in a hydrophilic core, so that the HM-Fe complex can be used as a good carrier for delivering CA4, and the problem of poor water solubility of CA4 is effectively solved. The liposome is co-modified by AS1411 and ApoE peptide, so that dual active targeting of liver cancer cells and tumor vascular endothelial cells can be realized, the in-vitro uptake efficiency is effectively improved, and the enrichment efficiency of a drug at a tumor part is remarkably improved; the system is high in stability, low in toxicity, efficient, good in biocompatibility, high in tumor inhibition rate and good in tumor inhibition effect and safety.

The invention relates to the field of medicinal chemistry, in particular to a preparation method of boron-containing embolism microspheres for boron neutron capture therapy, which is used for solving the problems that the existing boron medicine has no tumor targeting property and is limited in treatment effect. According to the preparation method, the boron medicine is coated to form the microspheres, and the embolization microspheres containing the boron medicine are blocked at the tumor part through an intervention means, so that the preparation method has the three advantages that firstly, passive targeting is realized, and the microspheres release the boron medicine at the tumor part because the microspheres are blocked at the blood supply vessel of the tumor; controllable release of the medicine is achieved, distribution of the boron medicine in other tissues and organs is reduced, and side effects of the boron medicine are reduced; and thirdly, the microspheres can carry a chemotherapy drug or a developing agent while carrying a boron drug, so that the combination of boron neutron capture therapy and chemotherapy is realized, and the treatment effect is remarkably improved.

The present application belongs to the technical field of biological macromolecule pharmaceutical chemistry and tumor targeting delivery system, and particularly relates to a polypeptide conjugate based on linaclotide and a preparation method and application thereof. The present application finds through experiments that linaclotide or its derivative has potential in colorectal cancer (CRC) targeting and deep penetration after proper modification, and therefore proposes a new use of the clinical drug linaclotide or its derivative in a tumor targeting drug delivery system, and constructs a polypeptide conjugate based on linaclotide or its derivative and a tumor targeting drug delivery system based thereon. In-vivo and in-vitro experiments prove that the polypeptide conjugate and the tumor targeting drug delivery system of the present application have precise targeting and deep penetration capabilities in colorectal cancer and metastatic tumors, can effectively enhance the accumulation of an antitumor drug at a tumor site, thereby enhancing the efficacy of the antitumor drug, and have a wide application prospect in the drug delivery system of colorectal cancer.

The invention discloses a pH response type double-drug targeting liposome, a preparation method thereof and application of the pH response type double-drug targeting liposome in pancreatic cancer treatment, a functional structure unit DSPE-hyd-PEG2000-RGD is obtained by organically combining a pH sensitive hydrazone bond with a targeting peptide, so that a liposome interface structure with stable circularity and environmental responsiveness is constructed; meanwhile, an anti-pancreatic cancer drug with a synergistic immune activation and metabolism regulation effect is entrapped in the lipidosome, a targeting-triggering-drug release integrated mechanism is formed, the lipidosome can realize a dual anti-tumor mechanism of immune activation and metabolism remodeling, the efficiency of accumulation of the drug at a tumor site and delivery in cells is effectively improved, and the anti-pancreatic cancer effect is improved. The treatment safety is improved, the systemic toxicity is reduced, and good clinical transformation potential is achieved; the preparation method is simple, convenient and high in repeatability, and the prepared liposome is good in stability and has good industrialization potential.

This invention discloses a pH-sensitive norcantharidin solid self-microemulsion, its preparation method, and its applications, belonging to the field of pharmaceutical technology. It comprises the following components in parts by weight: 0.1–3 parts norcantharidin, 1–10 parts pH-sensitive polymer, 30–80 parts solid adsorbent, and 87–98.9 parts blank self-microemulsion. The pH-sensitive norcantharidin solid self-microemulsion of this invention can improve the solubility and permeability of the drug. Due to the amide bond cleavage of the pH-sensitive polymer under acidic conditions, the drug is released systematically from the interior of the nano-solid self-microemulsion, resulting in targeted release at the tumor site. Animal experiments show that the pH-sensitive norcantharidin solid self-microemulsion of this invention can effectively improve the absorption rate constant and apparent permeability coefficient of norcantharidin at the colon tumor site, thereby enhancing its ability to inhibit tumor growth, migration, and invasion, and thus significantly improving the therapeutic effect of colon tumors.

This invention belongs to the field of lipid nanoparticle preparation technology, specifically relating to a zwitterionic modified lipid nanoparticle, its preparation method, and its application. The zwitterionic modified lipid nanoparticle includes a lipid nanoparticle matrix and a lipid derivative modified on its surface, wherein the lipid derivative is a zwitterionic modified polypeptide; and the zwitterion is DSPE-PEG. The lipid nanoparticles of this invention possess a strong hydration layer, which can significantly reduce the production of APA in vivo, avoiding the ABC effect associated with repeated injections. In the presence of APA in vivo, it can reduce the impact of APA on the interaction between liposomes and immune cells, reduce the phagocytosis and clearance of lipid nanoparticles by the mononuclear phagocytic system, and prolong blood circulation time. Even with high levels of APA in vivo, it can still accumulate at the tumor site, further improving the therapeutic effect and providing an effective strategy to avoid the ABC effect.

The invention discloses a medicine composition which comprises a first medicine component and a second medicine component. The first drug component comprises a fusion protein molecule comprising a fragment capable of binding to IL-15 or an IL-15 mutant, such as an IL-15R [alpha] or an IL-15R [alpha] sushi domain; the second drug component comprises an IL-15 drug molecule. The first drug component and the second drug component are used for sequential administration, preferably the first drug component is administered first and then the second drug component is administered. According to the composition, precise targeting is achieved through space-time reconstruction, IL-15 is captured after fusion protein is enriched at a tumor site, and a local high-concentration immune activation center is formed, so that the anti-tumor curative effect is remarkably enhanced, and meanwhile the systemic toxicity is reduced. The invention also relates to a fusion protein molecule, an IL-15 drug molecule, an administration method and an application of the fusion protein molecule, the IL-15 drug molecule and the administration method in preventing or treating interleukin 15 related tumors (such as liver cancer, breast cancer, lymphoma and the like).

The application belongs to the field of liposome drug delivery, and relates to a hypoxia-responsive prodrug liposome and a preparation and application thereof. The liposome contains a hypoxia-responsive prodrug and a photosensitizer, wherein the mass ratio between the hypoxia-responsive prodrug and the photosensitizer is 10:1-1:10; the hypoxia-responsive prodrug is a poorly soluble antitumor drug modified by a polyphenol. The hypoxia-responsive liposome prepared by the application has uniform particle size, high encapsulation efficiency and high drug loading capacity, good stability, significantly prolonged drug in-vivo circulation time and tumor site accumulation, and significantly improved antitumor effect. At the same time, the co-loaded liposome maintains fluorescence quenching in blood circulation, and specifically restores active oxygen capacity under the action of high glutathione in the tumor site, solving the problem of traditional photosensitizer phototoxicity.

The application discloses a kind of pemetrexed liposome and its preparation method and application, it is made of including 2mg / mL~20mg / mL pemetrexed or its pharmaceutically acceptable salt, 2.2mg / mL~12mg / mL cholesterols, 6.81mg / mL~108mg / mL neutral lipid, 12mg / mL~98mg / mL cationic lipid and 0.12mg / mL~2.12mg / mL PEG-lipid.The pemetrexed liposome of the application can significantly improve the enrichment of pemetrexed drug in tumor site, thereby enhancing drug treatment effect, reducing dosing dose, reducing the toxic side effects of drug on normal tissue.And it has good stability, no obvious change in storage process nature, particle size, zeta potential and encapsulation efficiency.

The present disclosure relates to the technical field of biological medicine, in particular to a polypeptide targeting PD-L1 and use thereof. The polypeptide provided by the present disclosure has high affinity and good stability. Based on the RDC of the polypeptide, the tumor primary lesion or metastatic lesion can be precisely targeted, and the polypeptide will not be retained in the tissues near the tumor and the tissues in non-tumor parts of the whole body, and the polypeptide can also avoid being rapidly degraded by proteases.

This invention addresses the lack of auxiliary devices for targeted radiation to the tumor site in existing intestinal implantation therapy. It provides a novel fixation mold for a rectal brazing radiotherapy applicator, comprising a connecting base and an implantation column. The implantation column is fixedly mounted on one side of the connecting base, which has connecting holes for connecting to external structures. The implantation column contains implantation holes parallel to its axis, distributed at equal angles around the axis of the column. These holes penetrate both the connecting base and the implantation column. By providing several equally angled implantation holes, it is easier to control the uneven distribution of implantation needles to correspond to eccentric rectal cancer tumors, thus achieving a more rational arrangement of the implantation needles.

The invention discloses a preparation method and application of resveratrol prodrug-obeticholic acid nanoparticles, and the preparation method comprises the following steps: (1) dissolving resveratrol in an organic alkali and a solvent, dropwise adding an oxalyl chloride solution for reaction, then adding mPEG-OH for continuous stirring, after the reaction is finished, removing the solvent, and performing dialysis and freeze drying to obtain a Res prodrug polymer PRO; (2) PRO and OCA are dissolved in an organic solvent, deionized water is slowly added under stirring to achieve self-assembly, then PRO / OCANPs is obtained through dialysis, and the nanoparticles aim at specifically targeting tumor sites and are decomposed to release Res and OCA under the action of ROS in a tumor microenvironment, so that the treatment effect is achieved to the maximum extent.